Potent peroxisome proliferator-activated receptor-  agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

(2014) Kausik K. Ray et al.   EUROPEAN HEART JOURNAL

HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

(2014) Anand Rohatgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels But Not Metrics of Functionality

(2013) Amit V. Khera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Peroxisome Proliferator-Activated Receptor-α Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor–Dependent Pathway

(2011) Kazuhiro Nakaya et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis

(2011) Amit V. Khera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

(2008) John S. Millar et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY